Edition:
United States

Kamada Ltd (KMDA.TA)

KMDA.TA on Tel Aviv Stock Exchange

1,667.00ILa
19 Sep 2017
Change (% chg)

0.00 (+0.00%)
Prev Close
1,667.00
Open
1,660.00
Day's High
1,667.00
Day's Low
1,647.00
Volume
107,236
Avg. Vol
123,235
52-wk High
2,920.00
52-wk Low
1,481.00

Chart for

About

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes... (more)

Overall

Beta: 0.42
Market Cap(Mil.): ₪668.05
Shares Outstanding(Mil.): 40.25
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

BRIEF-Kamada announces CFO transition

* Kamada Ltd - Gil Efron, (deputy CEO) & Chief Financial Officer (CFO), recently informed company of his plan to leave at end of year

Sep 18 2017

BRIEF-Brosh Capital's Amir Efrati reports 6.2 pct stake in Kamada Ltd

* Brosh Capital Partners LP's Amir Efrati reports 6.2 Pct stake in Kamada Ltd as of Sept 1 - SEC filing Source text: (http://bit.ly/2h49AAz) Further company coverage:

Sep 13 2017

BRIEF-Kamada announces pricing of public offering of ordinary shares

* Kamada Ltd - pricing of 3.33 million of its ordinary shares at a price of $4.50 per share Source text for Eikon: Further company coverage:

Jul 28 2017

BRIEF-Kamada to withdraw European Marketing Authorization application for inhaled ALPHA-1 antitrypsin

* Kamada announces withdrawal of European Marketing Authorization application for inhaled ALPHA-1 antitrypsin for treatment of ALPHA-1 antitrypsin deficiency disease

Jun 22 2017

BRIEF-Kamada receives additional milestone payment from Shire PLC

* Kamada receives additional milestone payment under Glassia exclusive supply and distribution agreement with Shire

Jun 12 2017

BRIEF-Kamada provides update on clinical program for alpha-1 antitrypsin IV treatment

* Provides update on clinical program for alpha-1 antitrypsin IV for treatment of graft-versus-host disease

Jun 07 2017

BRIEF-Kamada Q1 loss per share $0.11

* Kamada ltd says for 2017, continues to expect proprietary products revenues between $76 to $78 million and distributed products revenues between $22 to $24 million Source text for Eikon: Further company coverage:

May 16 2017

Earnings vs. Estimates